Aim Immunotech Stock Price, News & Analysis

AIM ImmunoTech announced that the FDA has lifted the clinical hold on its Phase 2 study of Ampligen for advanced pancreatic cancer, allowing the trial to proceed. Preliminary data suggests Ampligen may improve survival rates following FOLFIRINOX chemotherapy. The upcoming trial, AMP-270, aims to enroll about 90 subjects across 30 centers in the U.S. and Europe, assessing efficacy and safety compared to a no-treatment control. This milestone enhances the potential treatment landscape for pancreatic cancer, which currently has limited options.

AIM ImmunoTech Inc. has announced the acceptance of data from its ongoing Phase 2 clinical study of Ampligen® (rintatolimod) for treating cisplatin-resistant advanced recurrent ovarian cancer. The data will be presented at the AACR Annual Meeting 2022, scheduled for April 8-13 in New Orleans. This single-arm trial, conducted by the University of Pittsburgh Medical Center, shows promising results with a clinical benefit rate of 61.6% among 13 evaluable patients. The study aims to confirm these findings while enhancing our understanding of the tumor microenvironment.

AIM ImmunoTech Inc. (NYSE: AIM) announced that its drug candidate, Ampligen®, will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2022. Oncology experts from Roswell Park Comprehensive Cancer Center will share findings from two ongoing clinical studies involving Ampligen®. The first study evaluates a chemokine-modulatory regimen in colorectal cancer patients, while the second focuses on enhancing cytotoxic T-lymphocyte influx in metastatic triple-negative breast cancer. Both presentations are scheduled for April 11, 2022, in New Orleans, Louisiana.

AIM ImmunoTech announced promising data regarding Ampligen^® (rintatolimod) as a treatment for advanced pancreatic cancer in an Early Access Program at Erasmus Medical Center. The treatment showed a median overall survival of 19 months versus historical controls of 7.5 and 12.5 months. A Phase 2 study is set to begin in 2022, aiming to evaluate Ampligen's efficacy post-FOLFIRINOX. The study's positive endpoints include improved survival rates and increased B-cell counts, providing hope for patients with limited treatment options.

AIM ImmunoTech Inc. has announced the sale of its New Brunswick, New Jersey facility for $3.9 million. This strategic move aims to reduce operational expenses by over $1 million annually, allowing the company to focus on advancing its oncology and long-COVID clinical programs. CEO Thomas Equels emphasized the importance of this transaction in streamlining their processes toward FDA and EMA drug approvals. AIM will retain access to the facility for specific activities and plans to lease additional space for product development.

AIM ImmunoTech Inc. has appointed Robert Dickey IV as its new Chief Financial Officer, effective April 4, 2022. Dickey, a financial leader with over 25 years of experience in life sciences and medical devices, replaces Ellen Lintal, who will transition to a consulting role. AIM is poised for significant growth with six ongoing oncology clinical trials and multiple data readouts expected within the next year. The company believes Dickey's extensive background in capital markets and business development will bolster its strategic initiatives.

AIM ImmunoTech has announced participation in a webinar on January 27, 2022, from 2:00 PM to 3:00 PM ET, focusing on the clinical plans for the investigational drug Ampligen in treating myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long COVID.

The session will feature key executives discussing the drug's development, which has shown promise in improving cognitive function among patients. Attendees can register for the event through the provided link.

AIM ImmunoTech announced positive results from a Phase 1/2 clinical study on its intraperitoneal chemo-immunotherapy for advanced recurrent ovarian cancer. The study, demonstrating a well-tolerated safety profile, involved 12 patients and highlighted a 55.6% overall response rate and a median overall survival of 30 months. The promising results support the advancement to a Phase 2 trial, evaluating the immunologic and clinical efficacy of a tumor-loaded αDC1 vaccine combined with cisplatin and chemokine modulation. This development is expected to provide hope for patients and create shareholder value.

AIM ImmunoTech Inc. (NYSE: American AIM) announced a live video webcast presentation on January 26, 2022, at 10:00 AM ET during the Virtual Investor 2022 Top Picks Conference. CEO Thomas K. Equels will present the company’s advancements in therapeutics for cancer, immune disorders, and viral diseases, including COVID-19. The event will feature a corporate presentation followed by an interactive Q&A session. Interested parties may submit questions live or in advance. The presentation will be accessible via the company's website, with a replay available for one year.